title: Clinical description and evolution of renal transplant pediatric patients treated with alemtuzumab.
abstract: BACKGROUND
  Renal transplantation is the most effective treatment for children with end-stage renal disease. Recent work suggests that induction with alemtuzumab in the pediatric population permits the use of lower doses of maintenance immunosuppressive therapy. In addition, it has a low cost compared with other induction therapies.
  
  
  OBJECTIVE
  To conduct a clinical description of pediatric renal transplant patients comparing induction protocols to evaluate graft and patient survival, infections complications, and lymphoproliferative diseases.
  
  
  METHODS
  This descriptive and retrospective study, of evaluated pediatric renal transplant patients between 2006 and 2010.
  
  
  RESULTS
  The agents for induction therapy were: alemtuzumab (61.5%), daclizumab (19.25%), and thymoglobulin (19.25%). Graft survival was better among the alemtuzumab group (87.5%) compared with the other two induction therapies (80%). The frequency of acute rejection episodes during the first year posttransplantation as well as chronic rejection was lower among the alemtuzumab group. Cytomegalovirus infection was noted in 30% of patients with greater frequency among those induced with alemtuzumab.
  
  
  CONCLUSIONS
  Induction therapy with alemtuzumab was safe in a pediatric population not predisposing to a greater risk of acute or chronic rejection. Except for a greater incidence of Cytomegalovirus, there was no difference in other complications.
authors.affiliation: Department of Pediatric Nephrology, Pablo Tobón Uribe Hospital, Medellín, Colombia.
authors.forename: C
authors.initials: C
authors.lastname: Velez
authors.forename: G
authors.initials: G
authors.lastname: Zuluaga
authors.forename: C
authors.initials: C
authors.lastname: Ocampo
authors.forename: A
authors.initials: A
authors.lastname: Aristizabal
authors.forename: L M
authors.initials: LM
authors.lastname: Serna
authors.forename: A K
authors.initials: AK
authors.lastname: Serrano Gayubo
authors.forename: J A
authors.initials: JA
authors.lastname: Florez
authors.forename: J J
authors.initials: JJ
authors.lastname: Zuleta
authors.forename: J J
authors.initials: JJ
authors.lastname: Vanegas Ruiz
mesh_terms: D000293:Adolescent; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D003586:Cytomegalovirus Infections / Q000150:complications; D000077561:Daclizumab; D005260:Female; D006085:Graft Survival; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000379:methods*; D008232:Lymphoproliferative Disorders / Q000209:etiology; D008297:Male; D010372:Pediatrics / Q000379:methods; D051437:Renal Insufficiency / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum; D000970:Antineoplastic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D000077561:Daclizumab; C512542:thymoglobulin